Antibiotic levels in breast milk under the microscope
NCT ID NCT07645235
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study measures how much of the antibiotic gepotidacin passes into breast milk after a single 3000 mg dose. Eight healthy lactating women will provide milk and blood samples over 72 hours. The goal is to understand drug exposure for nursing infants, which could guide future use in breastfeeding mothers with urinary tract infections.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
gepotidacin
What this could lead to
If successful, this study could help determine whether gepotidacin is safe to use in breastfeeding women with urinary tract infections.
What could go wrong
This is a very small, early-phase study in healthy women, not patients. It only looks at drug levels, not safety or effectiveness in treating infections.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for URINARY TRACT INFECTIONS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••